Small-molecule inhibitors of biofilm formation in laboratory and clinical isolates of Free

Abstract

cells have the ability to form biofilms on biotic and abiotic surfaces, such as indwelling medical devices. cells can interconvert between budded and hyphal growth forms, herein termed the budded-to-hyphal transition (BHT), which is important for the formation of mature biofilms. Previous work identified 23 small organic molecules that could inhibit the BHT but did not affect cell viability or budded cell growth. These BHT inhibitors were proposed to inhibit multiple signalling pathways regulating the BHT, many of which also regulate biofilm formation. However, only three of the BHT inhibitors, buhytrinA, ETYA and CGP-37157, were capable of inhibiting biofilm formation of wild-type laboratory strains. When clinical isolates were examined for their ability to form biofilms, only 11 of the 28 clinical isolates tested (39 %) were capable of forming biofilms. Although buhytrinA, ETYA and CGP-37157 could inhibit the BHT of all 28 clinical isolates, they were only able to inhibit biofilm formation of a subset of these clinical isolates, with ETYA having 100 % efficacy. These data indicate that the biofilm-forming capability of laboratory and clinical isolates of , as well as the efficacy of BHT inhibitors against these different isolates, can differ dramatically. These differences between laboratory and clinical isolates should be an important aspect to consider when examining potentially new antifungal therapeutics.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.034124-0
2012-01-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/1/109.html?itemId=/content/journal/jmm/10.1099/jmm.0.034124-0&mimeType=html&fmt=ahah

References

  1. Agarwal V., Lal P., Pruthi P., Pruthi V. 2008; Studies of Candida albicans biofilm formed on biomaterial surfaces. J Biotechnol 136:S451 [View Article]
    [Google Scholar]
  2. Alem M. A. S., Douglas L. J. 2005; Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol 54:1001–1005 [View Article][PubMed]
    [Google Scholar]
  3. Biswas S., Van Dijck P., Datta A. 2007; Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans. Microbiol Mol Biol Rev 71:348–376 [View Article][PubMed]
    [Google Scholar]
  4. Blankenship J. R., Mitchell A. P. 2006; How to build a biofilm: a fungal perspective. Curr Opin Microbiol 9:588–594 [View Article][PubMed]
    [Google Scholar]
  5. Brown A. J. P. 2002; Morphogenetic signaling pathways in Candida albicans. In Candida and Candidiasis pp. 95–106 Edited by Calderone R. A. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  6. Brown A. J. P., Gow N. A. R. 1999; Regulatory networks controlling Candida albicans morphogenesis. Trends Microbiol 7:333–338 [View Article][PubMed]
    [Google Scholar]
  7. Chandra J., Mukherjee P. K., Ghannoum M. A. 2008; In vitro growth and analysis of Candida biofilms. Nat Protoc 3:1909–1924 [View Article][PubMed]
    [Google Scholar]
  8. Cox D. A., Conforti L., Sperelakis N., Matlib M. A. 1993; Selectivity of inhibition of Na(+)-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157. J Cardiovasc Pharmacol 21:595–599 [View Article][PubMed]
    [Google Scholar]
  9. d’Enfert C. 2006; Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 7:465–670 [View Article][PubMed]
    [Google Scholar]
  10. Gokce G., Cerikcioglu N., Yagci A. 2007; Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia 164:265–269 [View Article][PubMed]
    [Google Scholar]
  11. Jain N., Kohli R., Cook E., Gialanella P., Chang T., Fries B. C. 2007; Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 73:1697–1703 [View Article][PubMed]
    [Google Scholar]
  12. Kojic E. M., Darouiche R. O. 2004; Candida infections of medical devices. Clin Microbiol Rev 17:255–267 [View Article][PubMed]
    [Google Scholar]
  13. Liu H., Köhler J., Fink G. R. 1994; Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 266:1723–1726 [View Article][PubMed]
    [Google Scholar]
  14. Lynch A. S., Robertson G. T. 2008; Bacterial and fungal biofilm infections. Annu Rev Med 59:415–428 [View Article][PubMed]
    [Google Scholar]
  15. Mitchell A. P. 1998; Dimorphism and virulence in Candida albicans. Curr Opin Microbiol 1:687–692 [View Article][PubMed]
    [Google Scholar]
  16. Nobile C. J., Mitchell A. P. 2005; Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol 15:1150–1155 [View Article][PubMed]
    [Google Scholar]
  17. Nobile C. J., Mitchell A. P. 2006; Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8:1382–1391 [View Article][PubMed]
    [Google Scholar]
  18. Nobile C. J., Andes D. R., Nett J. E., Smith F. J., Yue F., Phan Q.-T., Edwards J. E., Filler S. G., Mitchell A. P. 2006; Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2:e63 [View Article][PubMed]
    [Google Scholar]
  19. Noverr M. C., Erb-Downward J. R., Huffnagle G. B. 2003; Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev 16:517–533 [View Article][PubMed]
    [Google Scholar]
  20. Pfaller M., Diekema D. 2007; Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163 [View Article][PubMed]
    [Google Scholar]
  21. Ramage G., VandeWalle K., López-Ribot J. L., Wickes B. L. 2002; The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214:95–100 [View Article][PubMed]
    [Google Scholar]
  22. Sherman F., Fink G. R., Hicks J. B. 1986 Methods in Yeast Genetics: Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  23. Shin J. H., Kee S. J., Shin M. G., Kim S. H., Shin D. H., Lee S. K., Suh S. P., Ryang D. W. 2002; Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 40:1244–1248 [View Article][PubMed]
    [Google Scholar]
  24. ten Cate J. M., Klis F. M., Pereira-Cenci T., Crielaard W., de Groot P. W. 2009; Molecular and cellular mechanisms that lead to Candida biofilm formation. J Dent Res 88:105–115 [View Article][PubMed]
    [Google Scholar]
  25. Toenjes K. A., Munsee S. M., Ibrahim A. S., Jeffrey R., Edwards J. E. Jr, Johnson D. I. 2005; Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 49:963–972 [View Article][PubMed]
    [Google Scholar]
  26. Toenjes K. A., Stark B. C., Brooks K. M., Johnson D. I. 2009; Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans. J Med Microbiol 58:779–790 [View Article][PubMed]
    [Google Scholar]
  27. Wilson R. B., Davis D., Mitchell A. P. 1999; Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol 181:1868–1874[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.034124-0
Loading
/content/journal/jmm/10.1099/jmm.0.034124-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed